How do pediatric pulmonology clinic nurses explain to Spanish-speaking parents why cystic fibrosis medication must continue when lung function has normalized on Trikafta?

The explanation requires establishing precisely what elexacaftor-tezacaftor-ivacaftor does at the molecular level and why the normalized FEV1 reflects the drug working rather than the disease resolving. Cystic fibrosis is caused by pathogenic variants in the CFTR gene, which encodes the cystic fibrosis transmembrane conductance regulator — a chloride and bicarbonate ion channel expressed on the apical surface of epithelial cells lining the airways, pancreatic ducts, intestine, and sweat gland tubules. The F508del variant (c.1521_1523delCTT; p.Phe508del) is the most common pathogenic variant, carried by approximately 90 percent of people with CF in the United States on at least one allele. F508del produces a CFTR protein in which phenylalanine at position 508 is absent. This single amino acid deletion disrupts the folding of the first nucleotide-binding domain (NBD1), producing a protein that the endoplasmic reticulum's quality control machinery — specifically the Hsp70/Hsp90 chaperone complex — identifies as misfolded. Rather than trafficking through the Golgi apparatus to the apical membrane, F508del CFTR is retained in the ER and routed to proteasomal degradation via the ERAD pathway. Less than one percent of F508del protein reaches the apical membrane under basal conditions, and the protein that does reach the surface is thermodynamically unstable and rapidly endocytosed. The cell surface has essentially no functional CFTR channel. Without CFTR-mediated chloride and bicarbonate secretion onto the airway surface, the airway surface liquid layer becomes depleted of water (because chloride secretion normally drives osmotic water movement onto the airway surface) and thickens. The mucus layer, which depends on a well-hydrated airway surface liquid for normal viscoelastic properties, becomes dehydrated, viscous, and adherent to the epithelial surface. Mucociliary transport — the coordinated beating of airway cilia that normally moves the mucus layer toward the larynx at approximately 3 to 8 mm per minute — cannot clear this thick, adherent mucus. Bacteria deposited in the airways are not cleared. Pseudomonas aeruginosa, Staphylococcus aureus, and Haemophilus influenzae colonize the retained mucus layer and trigger a self-amplifying neutrophilic inflammatory response: neutrophils recruited to the airway release neutrophil elastase and oxidants that directly damage the bronchial wall, driving the bronchiectasis that is the structural hallmark of CF lung disease. Elexacaftor, tezacaftor, and ivacaftor work through complementary mechanisms to rescue F508del CFTR. Elexacaftor is a next-generation CFTR corrector that binds to a hydrophobic groove at the interface of NBD1 and the membrane-spanning domain 1, stabilizing the misfolded protein and improving its folding efficiency in the ER. This allows a substantially increased fraction of F508del CFTR to pass ER quality control and traffic to the Golgi and then to the apical membrane. Tezacaftor is an earlier-generation corrector that provides additional stabilization to a different site on CFTR. Ivacaftor is a CFTR potentiator: it binds an allosteric site on CFTR's membrane-spanning domain and increases the probability that the channel is in the open configuration — the gating probability (Po) — from approximately 0.4 to 0.9. Together, elexacaftor and tezacaftor get more F508del protein to the apical membrane; ivacaftor keeps it open more of the time. The result is that CFTR-mediated chloride and bicarbonate secretion onto the airway surface is substantially restored. Sweat chloride — which measures CFTR channel function in the sweat gland and serves as a surrogate for airway CFTR function — falls from 104 mmol/L (diagnostic of CF) to 37 mmol/L (below the CF diagnostic threshold) on Trikafta. Airway surface liquid hydration is restored. Mucus viscosity normalizes. Mucociliary transport resumes. Bacterial colonization is reduced. FEV1 rises from 68 percent predicted to 95 percent predicted over eighteen months. The lung function is normal because the drug is continuously correcting the folding of new F508del CFTR protein as it is synthesized. It is not correcting the gene. Lucía's CFTR gene still encodes F508del on both alleles. Every newly synthesized CFTR protein will misfold in the ER as it has always done without the correctors present. The chaperone effect of elexacaftor requires elexacaftor to be present. If the drug is stopped, newly synthesized CFTR protein encounters the ER without the pharmacological chaperone, misfolds, and is degraded. The small amount of correctly folded CFTR at the apical membrane turns over with its normal cell-surface half-life of approximately 24 hours. Within one to three days of stopping Trikafta, CFTR surface expression is falling. Within one to two weeks, sweat chloride is rising back toward 104 mmol/L. The airway surface liquid begins to dehydrate. Mucus begins to thicken. Mucociliary transport declines. Bacterial colonization can resume. FEV1 follows with a lag, but the cascade that produces FEV1 decline has been reinitiated. The 95 percent predicted FEV1 is not evidence that Lucía's airways can maintain normal function without Trikafta. It is evidence that Trikafta is doing exactly what it should.

How do pediatric pulmonology clinic nurses explain to Spanish-speaking parents why ICS and LABA must continue in severe persistent asthma when the child has been symptom-free for eight months?

The explanation requires establishing that severe persistent asthma involves a continuous airway inflammatory process that is present independent of whether symptoms are present, and that the ICS is suppressing that process rather than treating acute symptoms. The most important diagnostic tool for understanding Valentina's asthma is the fractional exhaled nitric oxide measurement: FeNO 62 parts per billion. FeNO measures the concentration of nitric oxide in exhaled air, which is produced primarily in the airways by inducible nitric oxide synthase (iNOS) expressed in activated eosinophils and bronchial epithelial cells under the influence of Th2 cytokines, particularly IL-4 and IL-13. Normal FeNO in a child Valentina's age is below 20 ppb. A FeNO above 35 ppb indicates significant type 2 airway eosinophilic inflammation. At 62 ppb — measured three months ago at her last clinic visit, while she was on ICS — Valentina has a high eosinophilic inflammatory burden in her airways despite treatment. Her blood eosinophil count of 520 per microliter (above the normal upper limit of 500/μL and at the threshold for eosinophilic airway disease) corroborates this: eosinophils that are actively recruited to the airway originate from bone marrow progenitors and circulate in peripheral blood before tissue recruitment, and elevated peripheral blood eosinophilia reflects ongoing Th2 cytokine drive from the airway inflammatory process. Valentina has active eosinophilic airway inflammation measurable in real time, while on controller medication, after eight months without symptoms. The eosinophilic inflammatory process in severe persistent asthma is driven by the Th2 cytokine cascade: IL-4 and IL-13 from Th2 CD4+ T cells activate the IL-4Rα/IL-13Rα1 receptor complex on airway epithelial cells, driving the production of eotaxin-1 (CCL11) and CCL24, which recruit eosinophils from the circulation to the airway submucosa. IL-5 from Th2 cells and innate lymphoid cells type 2 (ILC2) promotes eosinophil maturation in the bone marrow and survival in the airway tissue, amplifying tissue eosinophilia. Eosinophils in the airway submucosa produce major basic protein, eosinophil cationic protein, and eosinophil peroxidase, which directly damage the bronchial epithelium, trigger neuronal hyperresponsiveness, and promote smooth muscle hypertrophy. The result is airway hyperresponsiveness — an abnormally low threshold for bronchospasm in response to triggers like cold air, exercise, viral infections, allergens, and irritants. This airway hyperresponsiveness is what causes asthma symptoms and exacerbations. The airway hyperresponsiveness is not an acute phenomenon that appears with symptoms and disappears between them. It is maintained by the ongoing eosinophilic inflammatory process in the airway submucosa, which is present continuously whether or not Valentina has symptoms on a given day. Fluticasone propionate, the ICS in the combination inhaler, is an inhaled corticosteroid that enters airway epithelial, subepithelial, and smooth muscle cells and binds intracellular glucocorticoid receptors (GRα). The GRα-fluticasone complex undergoes conformational change, dimerizes, translocates to the nucleus, and binds glucocorticoid response elements (GREs) in the promoter regions of anti-inflammatory genes — upregulating IκBα (which sequesters NF-κB in the cytoplasm, reducing pro-inflammatory gene transcription), MAPK phosphatase-1 (which inactivates the p38 MAPK inflammatory signaling pathway), and lipocortin-1 (which inhibits phospholipase A2 and reduces arachidonic acid-derived mediator production). Simultaneously, the GRα complex interacts with the p65 subunit of NF-κB and AP-1 transcription factors through transrepression mechanisms, reducing IL-4, IL-5, IL-8, TNF-α, and RANTES gene expression. The daily inhalation of fluticasone maintains this transcriptional suppression of the Th2 inflammatory cascade in airway tissue continuously. The eight months without exacerbation is not evidence that the asthma has resolved or that the ICS is not necessary. It is evidence that the ICS is continuously maintaining the transcriptional suppression that keeps eosinophil recruitment and airway hyperresponsiveness in check. If fluticasone is stopped, the GRα-mediated transcriptional program dissipates as the drug is no longer delivered to airway cells daily. NF-κB and AP-1 transcription factors resume normal activity. Th2 cytokine production increases. Eotaxin production increases. Eosinophil recruitment to the airway submucosa increases within two to four weeks. Airway hyperresponsiveness rises. The first viral upper respiratory infection, exercise bout in cold air, or allergen exposure will be significantly more likely to trigger a severe bronchospasm requiring oral corticosteroids or emergency department care than it would have been with ICS on board. In severe persistent asthma with FeNO 62 ppb and blood eosinophilia, the ICS is not treating acute symptoms. It is suppressing a continuous inflammatory process. The eight months of symptom freedom is the intended outcome of continuous ICS therapy — it disappears when the therapy does.

What are the key clinical Spanish phrases for the pediatric pulmonology clinic covering CF Trikafta continuation, PCD azithromycin prophylaxis, and severe persistent asthma ICS continuation?

For explaining CF Trikafta continuation when FEV1 is normal: 'La fibrosis quística de Lucía ocurre porque la proteína CFTR se pliega de forma incorrecta y el cuerpo la destruye antes de que llegue a la superficie de las células pulmonares. El medicamento — elexacaftor-tezacaftor-ivacaftor — es como un andamio molecular que ayuda a la proteína a doblarse correctamente mientras está siendo fabricada. El FEV1 de 95% NO significa que los pulmones se curaron — significa que el medicamento está funcionando ahora mismo. Si paramos el medicamento, no hay andamio, la proteína vuelve a plegarse mal, la capa de moco de los pulmones se vuelve pegajosa en días, y las bacterias empiezan a acumularse en semanas. Los pulmones necesitan el medicamento cada día porque el gen CFTR sigue siendo el mismo.' (Lucia's cystic fibrosis occurs because the CFTR protein folds incorrectly and the body destroys it before it reaches the surface of lung cells. The medication — elexacaftor-tezacaftor-ivacaftor — is like a molecular scaffold that helps the protein fold correctly while it is being made. FEV1 of 95% does NOT mean the lungs were cured — it means the medication is working right now. If we stop the medication, there is no scaffold, the protein folds incorrectly again, the mucus layer in the lungs becomes sticky within days, and bacteria start accumulating within weeks. The lungs need the medication every day because the CFTR gene is still the same.) For explaining PCD azithromycin prophylaxis: 'Los cilios de Sebastián no tienen los brazos de dineína que les permiten batir correctamente. Sin ese movimiento, el moco de sus pulmones no se mueve hacia afuera. Las bacterias que entran se quedan ahí. La azitromicina hace dos cosas al mismo tiempo: mata las bacterias antes de que causen infección, y reduce la inflamación que destruye las paredes de los bronquios. Los catorce meses sin hospitalizaciones son exactamente el resultado que buscamos — significan que la azitromicina está funcionando. Si la paramos, las bacterias se acumulan de nuevo, la inflamación regresa, y los bronquios se dañan de forma permanente con el tiempo.' (Sebastián's cilia do not have the dynein arms that allow them to beat correctly. Without that movement, the mucus in his lungs does not move outward. Bacteria that enter stay there. Azithromycin does two things simultaneously: it kills bacteria before they cause infection, and it reduces the inflammation that destroys the bronchial walls. The fourteen months without hospitalizations are exactly the outcome we are looking for — they mean the azithromycin is working. If we stop it, bacteria accumulate again, inflammation returns, and the bronchi are damaged permanently over time.) For explaining ICS continuation in severe persistent asthma when symptom-free: 'El asma grave de Valentina tiene inflamación activa en las vías respiratorias todos los días, aunque no tenga síntomas. La prueba de FeNO que hicimos mide directamente esa inflamación: 62 partes por billón significa que hay un nivel significativo de células eosinófilas activas en los bronquios ahora mismo, a pesar de que lleva ocho meses sin crisis. El inhalador con fluticasona suprime esa inflamación todos los días. Los ocho meses sin síntomas SON el inhalador funcionando. Si lo paramos, la inflamación regresa en dos a cuatro semanas, los bronquios se vuelven hipersensibles de nuevo, y la primera infección respiratoria o el ejercicio en aire frío pueden causar una crisis grave.' (Valentina's severe asthma has active inflammation in the airways every day, even when she has no symptoms. The FeNO test we performed measures that inflammation directly: 62 parts per billion means there is a significant level of active eosinophilic cells in the bronchi right now, despite eight months without a crisis. The inhaler with fluticasone suppresses that inflammation every day. The eight months without symptoms ARE the inhaler working. If we stop it, inflammation returns in two to four weeks, the bronchi become hyperresponsive again, and the first respiratory infection or exercise in cold air can cause a severe crisis.)

What are the most important communication challenges for Spanish-speaking families in the pediatric pulmonology clinic that translated handouts cannot adequately address?

Three structural communication challenges recur in pediatric pulmonology encounters with Spanish-speaking families and are not adequately addressed by translated educational materials alone. The first is the pharmacological chaperone concept in cystic fibrosis. Elexacaftor-tezacaftor-ivacaftor is a class of drug with no analogy in the family's prior medical experience: it does not treat the disease by eliminating its cause (the gene remains unchanged), does not treat symptoms as they occur (it prevents symptoms from occurring), and requires continuous daily administration for an effect that disappears within days of stopping. The family's natural framework for understanding medication — drawn from antibiotics that treat an infection until the infection is gone, or pain medications that are taken when pain is present and stopped when it is absent — does not apply. The concept that a medication is maintaining a molecular rescue of a permanently misfolded protein and that the rescue disappears the moment the medication does is not captured in handout language like 'take your medication as prescribed.' The nurse who can explain 'the medication is doing the folding work that your daughter's CFTR gene cannot do — every day, for every new protein molecule her body makes — and taking it away removes that work' is providing the conceptual model that makes the mechanism of discontinuation harm comprehensible. Sweat chloride as a concrete, measurable proxy helps: 'her sweat chloride went from 104 to 37 on this medication, which means the channel went from barely working to working normally — if we stopped the medication today, that number would go back to 104 within a week' makes the reversibility concrete and measurement-anchored in a way that 'your daughter needs this medication long term' cannot. The second challenge is the exacerbation-absence paradox in primary ciliary dyskinesia. A parent's lived experience of fourteen months without any respiratory hospitalization creates the strongest experiential evidence available to them that the azithromycin is not being used — nothing bad happened without the crisis it was supposed to prevent. The missing concept is that the absence of exacerbations is the medication's output, not proof that exacerbations would not have occurred without it. This is a counterfactual argument — what would have happened without the azithromycin — that cannot be proved directly for an individual patient. The parent cannot compare two timelines. What the nurse can do is make the mechanism of harm concrete and time-anchored: bronchiectasis from PCD does not appear dramatically as a crisis; it accumulates incrementally as each bacterial exacerbation leaves a small additional increment of bronchial wall fibrosis. The damaged airway does not recover. By the time bronchiectasis is visible on CT scan — typically in the lower lobes and right middle lobe, where drainage is poorest — years of inflammatory cycles have already occurred. The question of whether azithromycin is preventing individual hospitalizations is less important than whether it is preventing the bronchial wall damage that happens during each bacterial colonization cycle, even cycles that are managed at home. The nurse who says 'fourteen months without hospitalizations means the azithromycin is doing exactly what we hoped — every exacerbation it prevented is a small amount of bronchial wall damage that didn't happen' is converting the parent's success story from evidence against the treatment into evidence for it. The third challenge is measurement interpretation in asthma: specifically, FeNO as a direct measure of airway inflammation that is present independent of symptoms. Families understand asthma as an acute condition that produces visible symptoms — wheeze, shortness of breath, chest tightness, cough. Between acute episodes, the child is healthy, the asthma is quiet. This model, reinforced by every prior medical encounter focused on acute symptom management, makes ICS between exacerbations feel like unnecessary medication. The critical missing concept is that FeNO is a real-time measurement of the inflammatory process present in Valentina's airways right now, while she is sitting in the clinic without symptoms. If the handout says 'the ICS reduces airway inflammation,' the parent's response is 'but she is not having inflammation right now.' The nurse who can say 'I can show you a measurement of the inflammation in her airways taken right here today: 62 means there is a significant amount of eosinophilic inflammation active in her bronchi while she is sitting here symptom-free — the inhaler is suppressing that inflammation and the suppression disappears two to four weeks after we stop it' is replacing an abstract medication rationale with a concrete, current, in-this-visit measurement that proves the inflammatory process is present and the medication is addressing it.

Spanish for pediatric pulmonology clinic nurses — cystic fibrosis Trikafta continuation when FEV1 is normal, primary ciliary dyskinesia azithromycin prophylaxis, and severe persistent asthma ICS continuation when symptom-free

Three families in the pediatric pulmonology clinic share a structural communication challenge: each family observes a positive clinical outcome — normal lung function, fourteen months without hospitalization, eight months without an asthma crisis — and each family reasons from that outcome toward reducing or stopping a treatment, not understanding that the positive outcome is produced by the treatment working rather than by the disease resolving. Lucía’s FEV1 of 95% predicted is elexacaftor-tezacaftor-ivacaftor continuously rescuing F508del CFTR protein from endoplasmic reticulum retention and degradation; the CFTR gene encoding the misfolded protein is unchanged, and stopping the drug removes the pharmacological chaperone so that sweat chloride rises back toward 104 mmol/L within days. Sebastián’s fourteen exacerbation-free months are azithromycin preventing both bacterial colonization of the mucus that DNAI1-deficient cilia cannot clear and the neutrophilic inflammatory amplification that converts each colonization cycle into irreversible bronchial wall damage; the outer dynein arm defect confirmed by electron microscopy has not changed, and stopping azithromycin removes the two protective mechanisms that kept his airways free of the exacerbation-driven bronchiectasis pathway. Valentina’s eight symptom-free months are fluticasone’s glucocorticoid receptor-mediated transcriptional program continuously suppressing the eosinophilic Th2 airway inflammation confirmed by FeNO 62 ppb; the inflammatory process is present and measurable right now in her airway submucosa, and stopping ICS removes the transcriptional suppression so that eosinophil recruitment resumes within weeks and airway hyperresponsiveness returns before the first asthma symptoms announce its return.

Lucía Ramírez-Torres, 8 years old, Dallas, Texas — cystic fibrosis homozygous F508del, elexacaftor-tezacaftor-ivacaftor, FEV1 improved from 68% to 95% predicted, father requesting discontinuation

Lucía was diagnosed at three weeks of age through the Texas newborn screening program: immunoreactive trypsinogen elevated on two successive dried blood spot measurements, followed by confirmatory sweat chloride testing at 104 mmol/L (diagnostic threshold ≥60 mmol/L) and CFTR molecular testing confirming homozygous F508del (c.1521_1523delCTT; p.Phe508del) on both alleles. Initial pulmonary function testing at age five, after the CF center’s standard age threshold: FEV1 68% predicted. She began elexacaftor 200 mg / tezacaftor 150 mg / ivacaftor 300 mg once daily (with a 150 mg ivacaftor evening dose) at age six following FDA approval and center protocol extension to the 6–11 year age group. Eighteen months on therapy: FEV1 95% predicted, sweat chloride 37 mmol/L, no pulmonary exacerbations, Pseudomonas aeruginosa-free on surveillance sputum cultures.

Her father, Eduardo Ramírez-Cruz, forty-six, construction foreman, brings Lucía to her six-month pulmonology visit. He has been reading online about CFTR modulators and has found forum posts by parents asking the same question he is now asking directly: Lucía’s lung function is essentially normal. Her sweat test is now below the CF diagnostic threshold. She has had no infections in a year and a half. He wants to know if the disease has been cured and whether the medication can be stopped.

Nurse Daniela Fuentes-Vargas understands that Eduardo’s question follows logically from the data he is reading, and that the correct answer is counterintuitive. The conversation requires explaining what the drug is actually doing at the molecular level.

Cystic fibrosis is caused by loss-of-function pathogenic variants in the CFTR gene, which encodes the cystic fibrosis transmembrane conductance regulator — a member of the ABC transporter superfamily that functions as an anion channel on the apical surface of epithelial cells lining the airways, intestine, pancreatic ducts, and sweat gland tubules. CFTR’s primary function in the airways is chloride and bicarbonate secretion onto the airway surface: chloride secretion drives osmotic water movement onto the airway surface liquid (ASL) layer, maintaining its depth and hydration; bicarbonate secretion regulates mucus pH and gel properties. Without functional CFTR at the apical surface, the ASL layer is depleted of chloride and water, the mucus layer becomes dehydrated and viscous, and mucociliary transport fails.

The F508del variant removes a single phenylalanine residue at position 508 in the first nucleotide-binding domain (NBD1) of CFTR. This single amino acid deletion disrupts the normal folding of NBD1, producing a protein that the endoplasmic reticulum’s quality control machinery correctly identifies as misfolded. The major ER chaperone complex — Hsp70, Hsp40 co-chaperones, the E3 ubiquitin ligase CHIP, and associated factors — ubiquitinates F508del CFTR and routes it for proteasomal degradation via the ERAD pathway. Under basal conditions without pharmacological intervention, less than one percent of newly synthesized F508del CFTR escapes this quality control, traffics through the Golgi apparatus to the apical membrane, and reaches the cell surface. The small fraction that does reach the surface has impaired gating (reduced probability of being in the open conformation) and is thermodynamically unstable, with rapid internalization and degradation. For practical purposes, F508del CFTR produces no functional chloride channel at the airway epithelial apical surface.

Elexacaftor is a next-generation CFTR corrector. It binds a hydrophobic groove at the interface of NBD1 and membrane-spanning domain 1 (MSD1) of the misfolded F508del CFTR protein while the protein is still being synthesized and folding in the ER, acting as a pharmacological chaperone that stabilizes the NBD1 structure and partially corrects the folding defect. With elexacaftor present, a substantially increased fraction of F508del CFTR passes ER quality control, is not routed to ERAD, and traffics through the Golgi to the apical membrane. Tezacaftor, a first-generation corrector with a different binding site, provides additional stabilization that is additive with elexacaftor’s effect. Ivacaftor, a CFTR potentiator, binds an allosteric site on CFTR’s membrane-spanning domain after the protein has reached the cell surface and increases the gating probability — the fraction of time the channel spends in the open configuration — from the approximately 0.1 typical of surface-expressed F508del CFTR to approximately 0.6–0.9. Together, elexacaftor and tezacaftor increase the amount of F508del protein that reaches the apical membrane, and ivacaftor increases how effectively that protein functions as an ion channel when it gets there.

The result is that CFTR-mediated chloride and bicarbonate secretion onto the airway surface is substantially restored. Sweat chloride falls from 104 mmol/L to 37 mmol/L — below the CF diagnostic threshold of 60 mmol/L — because sweat gland tubule CFTR, which normally reabsorbs chloride from the sweat duct lumen, is now functional and chloride reabsorption occurs. Airway surface liquid hydration improves. Mucociliary transport resumes. Bacterial colonization pressure decreases. FEV1 rises from 68% predicted to 95% predicted as airways that were chronically inflamed and partially obstructed by thick mucus clear, and structural damage that had begun to accumulate is partially reversed by the restoration of normal mucociliary defense.

Every element of this improvement depends on elexacaftor being present at the CFTR protein while it is being synthesized in the ER. Elexacaftor is not fixing the CFTR gene. Lucía’s CFTR gene still encodes F508del on both alleles. Every ribosome that translates a new CFTR mRNA molecule will produce a new F508del protein that will misfold unless elexacaftor is present as it folds. CFTR protein at the apical membrane turns over continuously, with a half-life of approximately 24 hours for surface-expressed CFTR. If elexacaftor is not delivered to new CFTR protein being synthesized in the ER on any given day, those new molecules fold incorrectly, are routed to ERAD, and do not replace the surface CFTR molecules being internalized. Surface CFTR density begins to fall within one to three days of stopping the drug. Sweat chloride, which reflects real-time CFTR function in the sweat gland, begins rising within days. Within one to two weeks, sweat chloride approaches pre-treatment levels. ASL dehydration follows. Mucus viscosity increases. Mucociliary transport declines. Bacterial colonization can resume. FEV1 decline follows the mucus transport failure with a lag of weeks to months, but the cascade that produces it has been reinitiated the day the pharmacological chaperone is no longer present.

Nurse Daniela gives Eduardo a concrete reframe: the medication is doing the folding work that Lucía’s CFTR gene cannot do. Every day her body makes new CFTR protein. Every day, the medication is there to help it fold correctly. The 95% FEV1 is the medication’s daily work being reported back on a spirometry test. The day we take the medication away is the day the new CFTR protein starts folding incorrectly again — the sweat chloride test would show it within a week. The gene is the same as it was the day she was born. The medication is not a cure. It is a daily rescue of a protein that will always need rescuing.

Sebastián Torres-García, 6 years old, Houston, Texas — primary ciliary dyskinesia, DNAI1 biallelic, situs inversus totalis, azithromycin 250 mg three times weekly for 14 months, mother requesting discontinuation

Sebastián was referred to pediatric pulmonology at three years of age with recurrent otitis media requiring four sets of pressure equalization tubes by age two, chronic rhinosinusitis with persistent nasal congestion since birth, and a chest X-ray showing right-sided cardiac apex. The combination of neonatal respiratory distress (resolved), persistent respiratory symptoms from birth, and situs inversus prompted evaluation for primary ciliary dyskinesia. Nasal nitric oxide measurement was 38 nL/min on initial testing and 42 nL/min on repeat (reference range for normal ciliary function >77 nL/min). Nasal epithelial cell brushing was sent for transmission electron microscopy: outer dynein arms absent in 92% of ciliary cross-sections examined. DNAI1 molecular testing identified biallelic pathogenic variants: a paternally inherited missense variant (c.1462G>A; p.Glu488Lys) affecting a conserved WD-repeat domain residue and a maternally inherited frameshift (c.1474_1475del; p.Gln492Ilefs*8). The diagnosis: primary ciliary dyskinesia with outer dynein arm defect — Kartagener syndrome given the situs inversus totalis. Chest imaging at diagnosis confirmed dextrocardia and right-sided descending aorta.

Sebastián was started on airway clearance therapy twice daily with a positive expiratory pressure (PEP) mask device and azithromycin 250 mg three times weekly fourteen months ago. He has completed 61 weeks of azithromycin without a pulmonary exacerbation requiring hospital admission or a course of oral antibiotics, and without culture-documented Pseudomonas aeruginosa in respiratory specimens. His mother, Gabriela Torres-Vásquez, thirty-eight, elementary school teacher, has been researching long-term antibiotic effects and is concerned about antibiotic resistance and gut microbiome disruption. She asks whether the azithromycin can be stopped now that Sebastián has clearly been healthy without needing it.

Nurse Renata Espinoza-Cisneros understands that Gabriela’s concern about long-term antibiotics is medically legitimate and that her observation of Sebastián’s health is accurate. The conversation requires separating the outcome (Sebastián is well) from the inference (the azithromycin is not contributing to that outcome).

Motile cilia are hair-like organelles 5–7 micrometers long and 0.25 micrometers in diameter that extend from the apical surface of specialized epithelial cells lining the airways, fallopian tubes, brain ependyma, and the embryonic node. Their core structure is the axoneme: nine peripheral microtubule doublets arranged around a central pair, each doublet connected by nexin linkers and interdoublet links, with two sets of dynein arm projections extending from the A-tubule of each doublet toward the B-tubule of the adjacent doublet. Outer dynein arms — large, three-headed dynein motor complexes — are the primary force-generating structures. They use ATP hydrolysis at their motor domains to generate the power stroke that slides adjacent microtubule doublets past each other; constrained by the axonemal architecture, this sliding is converted to asymmetric bending, producing the effective stroke and recovery stroke that constitute the ciliary beat cycle. Normal human airway cilia beat at approximately 10–14 hertz with a planar waveform that transports the overlying mucus layer toward the larynx.

DNAI1 encodes the intermediate chain 2 of the outer dynein arm complex, which is required for the assembly and attachment of outer dynein arms to the A-tubule of axonemal microtubule doublets during ciliogenesis. Without functional DNAI1 protein, outer dynein arms fail to assemble correctly in the cytoplasm and cannot attach to the doublets. The axoneme lacks outer dynein arms throughout its length. Cilia adopt a normal 9+2 ultrastructure without outer dynein arms — visible on electron microscopy as axonemal profiles with inner dynein arms present but no outer dynein arm projections. Without outer dynein arms, cilia cannot generate normal beat frequency or amplitude. They produce slow, dyskinetic movement. Mucociliary transport velocity, normally 3–8 mm/min in the healthy human airway, is essentially zero in PCD with outer dynein arm defects. This ciliary defect is encoded in the DNAI1 gene on every chromosome 9 in every cell of Sebastián’s body. It was present at birth, confirmed by electron microscopy, and will be present in every ciliated cell his airway epithelium produces for the rest of his life.

The consequence of permanent absent mucociliary transport is that inhaled particulates and microorganisms deposited in the bronchial mucus layer are not removed. Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, and respiratory viruses that deposit in Sebastián’s bronchial mucus and in his upper airway mucosa remain. Bacterial growth in the retained mucus layer triggers the airway inflammatory response that is the primary driver of structural PCD lung disease: pattern recognition receptors (TLR2, TLR4) on airway epithelial cells and resident macrophages recognize bacterial wall components, activate NF-κB signaling, and produce IL-8 (CXCL8) — the primary neutrophil chemoattractant. Neutrophils recruited to the airway submucosa and lumen to address the bacterial colonization deploy their antimicrobial arsenal: neutrophil elastase, cathepsin G, matrix metalloprotease-9, myeloperoxidase, and reactive oxygen species. These agents are effective at bacterial killing but also directly digest the bronchial wall. Neutrophil elastase degrades airway cartilage and smooth muscle elastin, producing the cylindrical or varicose bronchial dilation and wall thickening that appears on high-resolution CT scan as bronchiectasis. Bronchiectasis in PCD accumulates with each exacerbation-inflammation cycle, is irreversible once established, and is the primary determinant of long-term pulmonary function in PCD patients.

Azithromycin in PCD provides two simultaneous protective mechanisms. The first is antimicrobial. Azithromycin is a macrolide antibiotic that achieves intracellular-to-extracellular concentration ratios of 10–100:1 in alveolar macrophages and bronchial epithelial cells, reaching tissue concentrations substantially above the minimum inhibitory concentration for H. influenzae, M. catarrhalis, and S. pneumoniae at the three-times-weekly dose. This reduces the bacterial load in Sebastián’s retained airway mucus and decreases the frequency and severity of bacterial exacerbations that would otherwise occur as bacteria colonize the non-cleared mucous layer. The second mechanism is anti-inflammatory and immunomodulatory, independent of antimicrobial activity. Azithromycin and the macrolide class suppress NF-κB-driven IL-8 production in bronchial epithelial cells, reduce neutrophil migration into the airway lumen, and modulate macrophage polarization toward a less pro-inflammatory phenotype. This effect was first demonstrated in diffuse panbronchiolitis, a related disease of impaired mucociliary clearance in Japanese patients, where continuous macrolide therapy improved five-year survival from approximately 30% to greater than 90% by interrupting the inflammatory amplification cycle. In PCD and CF, the anti-inflammatory macrolide effect reduces the neutrophil-elastase-driven structural damage that accumulates with each bacterial colonization cycle, even those not severe enough to require hospitalization.

Fourteen months without a pulmonary exacerbation requiring hospitalization or antibiotics means the azithromycin is doing exactly what it was started to do. Every week without a bacterial exacerbation is a week without the neutrophilic inflammatory response that deposits a small additional increment of bronchial wall damage. Gabriela’s concern about antibiotic resistance and gut microbiome impact is clinically valid — these are real effects of long-term macrolide use that the pulmonology team monitors with annual audiology (azithromycin carries low-level ototoxicity risk at prolonged use) and periodic stool culture if gastrointestinal symptoms emerge. The monitoring exists because the benefit-risk calculation has been performed and the benefit of preventing exacerbation-driven bronchiectasis outweighs the manageable adverse effect profile at this dose and schedule. Stopping azithromycin removes both protective mechanisms. Bacterial exacerbations resume in the non-cleared mucus layer. The inflammatory amplification cycle restarts. And the structural damage accumulates — not dramatically as a single visible event, but incrementally, bronchial segment by bronchial segment, until high-resolution CT shows bronchiectasis that was not there a year ago and will not resolve.

Valentina Cisneros-Cruz, 11 years old, San Antonio, Texas — severe persistent asthma, FeNO 62 ppb, eosinophils 520/μL, fluticasone/salmeterol 250/50 mcg twice daily, 8 months symptom-free, mother requesting ICS discontinuation

Valentina was diagnosed with persistent asthma at age seven following her third asthma exacerbation requiring emergency department management in twelve months: all three were triggered by viral upper respiratory infections during the school year and required two-day oral prednisolone courses. Spirometry at that visit demonstrated FEV1 81% predicted with 16% bronchodilator reversibility (FEV1 post-albuterol 94% predicted), confirming variable airflow obstruction. Skin prick testing was positive for house dust mite (8 mm) and cockroach (6 mm) allergens, both prevalent in San Antonio housing. She was started on inhaled corticosteroid monotherapy (fluticasone propionate 100 mcg twice daily) and subsequently stepped up to fluticasone/salmeterol 250/50 mcg twice daily plus montelukast 10 mg daily after two exacerbations in year two of treatment despite ICS compliance.

Most recent pulmonology visit three months ago: FEV1 92% predicted, no exacerbations in the preceding 8 months, blood eosinophil count 520/μL (elevated above normal upper limit of 500/μL), FeNO 62 ppb (normal <20 ppb in children; 25–50 ppb indicates moderate type 2 airway inflammation; >50 ppb indicates high type 2 eosinophilic inflammation). Today’s visit: Rosa Cisneros-Torres, forty-two, administrative coordinator, has read about long-term ICS side effects in children — growth suppression, hypothalamic-pituitary-adrenal axis suppression, bone density effects — and has decided that eight months without any crisis is proof that Valentina’s asthma is under control and the ICS can be stopped. She wants to discuss stepping down to montelukast alone.

Nurse Isabela Morales-Reyes understands that Rosa’s concerns about ICS side effects are scientifically grounded and that the eight months symptom-free is real and welcome. The conversation requires explaining what the FeNO measurement at Valentina’s last visit means and what the ICS is actually doing during those symptom-free months.

Fractional exhaled nitric oxide is a non-invasive measure of airway inflammation that can be performed in the clinic in approximately five minutes. The patient exhales at a controlled slow flow rate (50 mL/sec) through a mouthpiece that maintains a small expiratory pressure, and a chemiluminescent or electrochemical analyzer measures the concentration of nitric oxide in the exhaled air. The nitric oxide detected in this test is produced primarily in the bronchial airways — specifically in eosinophils and bronchial epithelial cells in the airway submucosa — by inducible nitric oxide synthase (iNOS), whose expression is upregulated by Th2 cytokines IL-4 and IL-13 through STAT6 signaling. A FeNO of 62 ppb means that Valentina’s airway submucosa contained enough iNOS-expressing eosinophils and epithelial cells to produce an exhaled nitric oxide concentration more than three times the upper limit of normal — on the most recent visit, during a period of complete symptom freedom. The FeNO is a direct, quantitative, real-time measurement of airway eosinophilic inflammation. It is not a prediction of future risk. It is a description of the inflammatory state present in Valentina’s airways at the time of the measurement.

The mechanism driving this inflammation is the Th2 cytokine cascade. In atopic asthma, environmental allergen exposure (house dust mite, cockroach protein) drives dendritic cells in the airway submucosa to present allergen peptides to CD4+ T cells in the context of costimulatory signals (OX40L, thymic stromal lymphopoietin) that direct T cell differentiation toward the Th2 phenotype. Th2 cells and innate lymphoid cells type 2 (ILC2) produce IL-4, IL-5, and IL-13 constitutively at a level maintained by ongoing allergen exposure, house dust mite and cockroach being perennial allergens in indoor San Antonio environments. IL-4 and IL-13 act on airway epithelial cells and subepithelial fibroblasts through the IL-4Rα/IL-13Rα1 receptor complex, driving eotaxin-1 (CCL11) and CCL24 production — the two primary eosinophil chemoattractants that recruit circulating eosinophils to the airway submucosa. IL-5 promotes eosinophil maturation in bone marrow progenitors and eosinophil survival in tissue, amplifying submucosal eosinophilia. Submucosal eosinophils produce major basic protein, eosinophil cationic protein, and eosinophil-derived neurotoxin, which sensitize airway smooth muscle and sensory nerves to bronchoconstrictive stimuli — producing airway hyperresponsiveness. This entire process runs continuously at a steady state determined by allergen exposure and the Th2 immune set-point, independent of whether Valentina is experiencing symptoms on any given day. The absence of symptoms means the hyperresponsiveness threshold has not been crossed by any particular trigger recently. It does not mean the inflammatory process driving the hyperresponsiveness is absent.

Fluticasone propionate, the inhaled corticosteroid in the combination inhaler, enters airway epithelial and subepithelial cells after inhalation and binds intracellular glucocorticoid receptors (GRα) with high affinity (relative affinity 1800, compared to dexamethasone 100 and hydrocortisone 1). The GRα-fluticasone complex undergoes conformational change, dimerizes, and translocates to the cell nucleus, where it: (1) binds positive glucocorticoid response elements (GREs) to upregulate IκBα (sequestering NF-κB in the cytoplasm and reducing pro-inflammatory transcription), MAPK phosphatase-1 (inactivating p38 MAPK inflammatory signaling), and lipocortin-1 (inhibiting phospholipase A2 and reducing arachidonic acid metabolite production); (2) undergoes transrepression interactions with p65 NF-κB and c-Fos/c-Jun (AP-1) transcription factor subunits, directly blocking their DNA binding and reducing IL-4, IL-5, IL-8, TNF-α, and RANTES gene transcription. The daily inhalation of fluticasone maintains this transcriptional suppression of the Th2 cytokine cascade in Valentina’s airway epithelial and submucosal cells continuously. The reduction in IL-4, IL-5, and IL-13 activity reduces eotaxin production, reduces eosinophil recruitment from the bone marrow and circulation, reduces eosinophil survival in airway tissue, and reduces the eosinophil-derived mediators that sensitize smooth muscle and nerves. FeNO falls from higher levels as iNOS expression in eosinophils is suppressed. Airway hyperresponsiveness is reduced because the eosinophilic process driving it is suppressed. Valentina has fewer or no asthma symptoms because the airway hyperresponsiveness threshold has been raised by the continuous inflammatory suppression — triggers that would have produced bronchospasm in the absence of ICS no longer cross the threshold when ICS is on board.

If fluticasone is stopped, the GRα-mediated transcriptional program dissipates as the drug is no longer delivered to airway cells with each twice-daily inhalation. NF-κB and AP-1 resume normal transcriptional activity in the absence of GRα transrepression. Th2 cytokine production increases as epithelial and submucosal cell gene expression returns to the steady state driven by ongoing allergen exposure. Eotaxin production increases. Eosinophil recruitment to the airway submucosa increases within two to four weeks of stopping ICS, as confirmed by bronchoalveolar lavage studies in asthmatic patients withdrawn from ICS in controlled clinical research settings. Airway hyperresponsiveness rises. The FeNO, measured three months ago at 62 ppb on ICS, would be expected to be higher off ICS as iNOS suppression is relieved. Valentina’s first viral upper respiratory infection, episode of heavy allergen exposure, or sustained exercise bout in cold air will be significantly more likely to trigger a severe bronchospasm requiring oral corticosteroids or emergency department care than it would have been with ICS on board. The symptomatic crisis will feel sudden and unexplained to the family, because the weeks of rising airway hyperresponsiveness preceding it will be invisible.

Nurse Isabela addresses Rosa’s ICS side effect concerns directly: the evidence on ICS growth effects at the 250 mcg fluticasone twice-daily dose in school-aged children shows a mean height effect of approximately 0.5 cm in the first year of treatment with no evidence of cumulative height deficit beyond year one, based on CAMP and PEAK trial data. The HPA axis suppression risk at standard ICS doses is small and clinically monitored. The risks Rosa read about are real considerations that are part of the treatment decision — and they are why the pulmonology team monitors height at every visit. They are also the reason the team uses the lowest effective ICS dose. At Valentina’s GINA step 4 requirement and FeNO 62 ppb, the ICS dose is calibrated to the inflammation present. What the FeNO measurement tells us is that the inflammation is present and substantial even while the ICS is suppressing it. If we step down to montelukast alone, leukotriene receptor antagonism addresses one pathway of the Th2 cascade — it does not suppress the upstream cytokine transcription that ICS controls. The FeNO would be expected to rise further off ICS. The next viral illness would have a substantially higher probability of producing the oral steroid course or ED visit Rosa is trying to avoid. The ICS side effect exposure is the consequence of giving treatment. The consequences of not giving it are the asthma exacerbations that the eight symptom-free months have been preventing.

The three scenarios in this post share a structural pattern across the pediatric pulmonology clinic: families who observe a positive clinical outcome — normal lung function, no hospitalizations for over a year, eight months without an asthma crisis — and reason from that positive outcome toward stopping an intervention, not understanding that the positive outcome is produced by the intervention working continuously. Lucía’s FEV1 of 95% predicted is the pharmacological chaperone doing daily rescue of F508del CFTR protein from ER retention; the gene producing that misfolded protein is unchanged, and stopping the drug removes the rescue within days. Sebastián’s fourteen exacerbation-free months are azithromycin preventing bacterial colonization cycles and the neutrophilic inflammatory amplification that converts each cycle into irreversible bronchial wall damage; the outer dynein arm defect has not changed, and stopping azithromycin removes both protective mechanisms simultaneously. Valentina’s eight symptom-free months are the glucocorticoid receptor-mediated transcriptional suppression of the Th2 eosinophilic inflammatory cascade that FeNO 62 ppb confirms is present and active in her airway submucosa; stopping ICS removes the transcriptional suppression and eosinophil recruitment resumes within weeks, before the next trigger produces the asthma crisis that will make the inflammation visible.

The nurse who understands these mechanisms can reframe each clinical conversation from “the outcome is good, so the treatment seems unnecessary” to “the outcome is good because the treatment is working, and the good outcome disappears when the treatment stops.” FEV1 95% means the Trikafta is doing its molecular chaperone work every day — stop it and sweat chloride rises within a week. Fourteen months without hospitalization means the azithromycin has been preventing the bacterial colonization and inflammatory damage that the absent outer dynein arms can never prevent on their own — stop it and the bacterial exacerbation cycle resumes into airways that have no permanent mucociliary defense. Eight months symptom-free means the fluticasone is maintaining transcriptional suppression of an eosinophilic inflammatory process that FeNO 62 ppb confirms is present and measured right now — stop it and eosinophil recruitment to the airway submucosa rises within weeks, before the first trigger makes the resulting airway hyperresponsiveness visible.

Six key Spanish phrases for the pediatric pulmonology clinic

El medicamento de Lucía no cura el gen de la fibrosis quística — lo que hace es ayudar a la proteína CFTR a doblarse correctamente cada día mientras el cuerpo la fabrica. Sin el medicamento, la proteína vuelve a plegarse mal y se destruye antes de llegar a la superficie de las células del pulmón. El FEV1 de 95% y el sudor normal son exactamente el resultado que buscamos — significan que el medicamento está funcionando ahora mismo. Si lo paramos, el test del sudor vuelve a subir en una semana y el moco de los pulmones vuelve a volverse pegajoso en pocas semanas. — Lucia's medication does not cure the cystic fibrosis gene — what it does is help the CFTR protein fold correctly every day while the body makes it. Without the medication, the protein folds incorrectly again and is destroyed before reaching the surface of the lung cells. FEV1 of 95% and normal sweat are exactly the result we are looking for — they mean the medication is working right now. If we stop it, the sweat test goes back up within a week and the lung mucus becomes sticky again within a few weeks.
El gen de Lucía sigue produciendo la proteína CFTR mal plegada cada día. El medicamento tiene que estar presente todos los días para ayudar a que cada nueva proteína se doble bien. No es un tratamiento que se toma hasta que los pulmones mejoran y luego se puede parar — es como los lentes: mientras los tiene puestos, ve bien. Cuando los quita, deja de ver bien. Los pulmones funcionan bien mientras el medicamento está actuando sobre la proteína nueva que se fabrica cada día. — Lucia's gene keeps producing the incorrectly folded CFTR protein every day. The medication must be present every day to help each new protein fold correctly. It is not a treatment taken until the lungs improve and then stopped — it is like glasses: while she has them on, she sees well. When she takes them off, she stops seeing well. The lungs function well while the medication is acting on the new protein that is made each day.
Los cilios de Sebastián no tienen los brazos motores que necesitan para mover el moco hacia afuera. Eso es permanente — no cambia con el tiempo ni con el tratamiento. Sin esos cilios funcionando, las bacterias que entran a los bronquios se quedan ahí. La azitromicina mata las bacterias antes de que causen infecciones y también reduce la inflamación que, con el tiempo, daña permanentemente las paredes de los bronquios. Los catorce meses sin hospitalizaciones son el resultado que queríamos — significan que el medicamento está haciendo exactamente lo que se diseñó para hacer. — Sebastián's cilia do not have the motor arms they need to move mucus outward. That is permanent — it does not change with time or treatment. Without those cilia functioning, bacteria that enter the bronchi stay there. Azithromycin kills bacteria before they cause infections and also reduces the inflammation that, over time, permanently damages the bronchial walls. The fourteen months without hospitalizations are the result we wanted — they mean the medication is doing exactly what it was designed to do.
Cada vez que los bronquios de Sebastián se infectan, las células del sistema inmune dejañan un poco la pared del bronquio aunque el niño se recupere. Con el tiempo, ese daño acumulado es lo que vemos como bronquiectasias en el CT — bronquios dilatados permanentemente. La azitromicina interrumpe ese ciclo. Si la paramos, las bacterias vuelven a colonizar el moco, las infecciones regresan, y el daño se acumula semáforo a semáforo, sin que se note hasta que la imagen ya lo muestra. — Every time Sebastián's bronchi get infected, the immune system cells leave a little damage to the bronchial wall even if the child recovers. Over time, that accumulated damage is what we see as bronchiectasis on CT — permanently dilated bronchi. Azithromycin interrupts that cycle. If we stop it, bacteria re-colonize the mucus, infections return, and the damage accumulates step by step, without being noticed until imaging already shows it.
El resultado de FeNO que hicimos en la última visita — 62 partes por billón — es una medición directa de cuánta inflamación eosinofílica tiene Valentina en los bronquios ahora mismo, mientras está sin síntomas. Un valor normal es menos de 20. El de Valentina es 62 a pesar de llevar meses con el inhalador. Eso significa que hay una cantidad importante de inflamación activa en los bronquios todos los días. Los ocho meses sin crisis son el inhalador suprimiendo esa inflamación cada día. Si paramos el inhalador, la inflamación vuelve en dos a cuatro semanas, antes de que llegue cualquier síntoma. — The FeNO result we got at the last visit — 62 parts per billion — is a direct measurement of how much eosinophilic inflammation Valentina has in her bronchi right now, while she is without symptoms. A normal value is less than 20. Valentina's is 62 despite being on the inhaler for months. That means there is a significant amount of active inflammation in the bronchi every day. The eight months without crises are the inhaler suppressing that inflammation every day. If we stop the inhaler, inflammation returns in two to four weeks, before any symptom arrives.
Los efectos secundarios del inhalador que la mamá leyó son reales y los monitoreamos: medimos la talla de Valentina en cada visita exactamente por eso. A la dosis que usa Valentina, el efecto promedio en el crecimiento en el primer año es de menos de medio centímetro, y después no se acumula. Ese efecto pequeño y monitoreado hay que compararlo con lo que pasa si paramos el inhalador cuando el FeNO es de 62: la próxima infección viral o el ejercicio intenso van a encontrar los bronquios mucho más reactivos, y la crisis que queremos evitar es la que requiere prednisona o urgencias. — The inhaler side effects that mom read about are real and we monitor them: we measure Valentina's height at every visit for exactly that reason. At the dose Valentina uses, the average growth effect in the first year is less than half a centimeter, and after that it does not accumulate. That small, monitored effect must be compared with what happens if we stop the inhaler when FeNO is 62: the next viral infection or intense exercise will find the bronchi much more reactive, and the crisis we want to avoid is the one that requires prednisone or the emergency room.

For related conditions in the pediatric pulmonology setting, see Spanish for pediatric endocrinology clinic nurses (covering levothyroxine continuation when TSH is normal in thyroid agenesis, CAH stress dosing after survived illnesses, and GH injection continuation when catch-up growth is normal), Spanish for pediatric epilepsy clinic nurses (covering ethosuximide continuation after a seizure-free EEG, valproate in Dravet syndrome, and post-ACTH EEG surveillance in infantile spasms), and Spanish for pediatric hematology clinic nurses (covering hydroxyurea continuation when Hb F is elevated and crises are absent, watchful waiting in chronic ITP, and penicillin prophylaxis after splenectomy).